Stock SWTX SPRINGWORKS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
45.11 USD +4.06% Intraday chart for SpringWorks Therapeutics, Inc. -0.92% +23.59%
05-02 Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating MT
05-02 SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss
SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Springworks Therapeutics Insider Sold Shares Worth $1,160,362, According to a Recent SEC Filing
SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Key Jobs Report Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday
SpringWorks Therapeutics Prices $275 Million Share Offering
SpringWorks Therapeutics Launches $250 Million Public Offering of Shares; Stock Falls After Hours
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell
SpringWorks non-cancerous tumor drug to be priced at $29,000 per month in US
SpringWorks Therapeutics Says FDA Approved Desmoid Tumors Treatment Ogsiveo
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO? (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
US FDA approves SpringWorks Therapeutics' non-cancerous tumor treatment
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
SpringWorks Therapeutics Reports 'Positive' Results from Trial of Neurofibromatosis Treatment
SpringWorks Therapeutics, Inc. Announces Positive Topline Results from the Phase 2B ReNeu Trial of Mirdametinib in NF1-PN
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SWTX Stock
  4. News SpringWorks Therapeutics, Inc.
  5. Other languages